Cargando…
Human anti-HIV IgM detection by the OraQuick ADVANCE® Rapid HIV 1/2 Antibody Test
The Centers for Disease Control and Prevention (CDC) and many public health jurisdictions continue to advocate for the most sensitive rapid HIV test that is available. Currently, the recommendation is to utilize tests that can detect HIV infection biomarkers within 30 days of infection, when initial...
Autores principales: | Guillon, Geraldine, Yearwood, Graham, Snipes, Casey, Boschi, Daniel, Reed, Michael R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834934/ https://www.ncbi.nlm.nih.gov/pubmed/29507828 http://dx.doi.org/10.7717/peerj.4430 |
Ejemplares similares
-
Correction: Human anti-HIV IgM detection by the OraQuick ADVANCE(®) Rapid HIV 1/2 Antibody Test
por: Guillon, Geraldine, et al.
Publicado: (2018) -
Performance Evaluation of the OraQuick Hepatitis C Virus Rapid Antibody Test
por: Cha, Young Joo, et al.
Publicado: (2013) -
Evaluation of the Performance of OraQuick Rapid HIV-1/2 Test Among Decedents in Kisumu, Kenya
por: Opollo, Valarie, et al.
Publicado: (2022) -
Field comparison of OraQuick® ADVANCE Rapid HIV-1/2 antibody test and two blood-based rapid HIV antibody tests in Zambia
por: Zachary, Dalila, et al.
Publicado: (2012) -
Re‐reading of OraQuick HIV‐1/2 rapid antibody test results: quality assurance implications for HIV self‐testing programmes
por: Watson, Victoria, et al.
Publicado: (2019)